These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

627 related articles for article (PubMed ID: 32483657)

  • 21. Sequence-Optimized mRNA Vaccines Against Infectious Disease.
    Rauch S; Lutz J; Mühe J; Kowalczyk A; Schlake T; Heidenreich R
    Methods Mol Biol; 2024; 2786():183-203. PubMed ID: 38814395
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Path towards mRNA delivery for cancer immunotherapy from bench to bedside.
    Chen W; Zhu Y; He J; Sun X
    Theranostics; 2024; 14(1):96-115. PubMed ID: 38164145
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of nanoparticle format and route of administration on self-amplifying mRNA vaccine potency.
    Anderluzzi G; Lou G; Woods S; Schmidt ST; Gallorini S; Brazzoli M; Johnson R; Roberts CW; O'Hagan DT; Baudner BC; Perrie Y
    J Control Release; 2022 Feb; 342():388-399. PubMed ID: 34896446
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Advances in mRNA Vaccines for Infectious Diseases.
    Zhang C; Maruggi G; Shan H; Li J
    Front Immunol; 2019; 10():594. PubMed ID: 30972078
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Advances in mRNA vaccines.
    Li M; Wang Z; Xie C; Xia X
    Int Rev Cell Mol Biol; 2022; 372():295-316. PubMed ID: 36064266
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recent Advances in the Molecular Design and Delivery Technology of mRNA for Vaccination Against Infectious Diseases.
    Yang L; Tang L; Zhang M; Liu C
    Front Immunol; 2022; 13():896958. PubMed ID: 35928814
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Transcutaneous delivery of DNA/mRNA for cancer therapeutic vaccination.
    Sun X; Zeng L; Huang Y
    J Gene Med; 2019 Jul; 21(7):e3089. PubMed ID: 30958606
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vaccination with Messenger RNA: A Promising Alternative to DNA Vaccination.
    Tombácz I; Weissman D; Pardi N
    Methods Mol Biol; 2021; 2197():13-31. PubMed ID: 32827130
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Comprehensive Review of mRNA Vaccines.
    Gote V; Bolla PK; Kommineni N; Butreddy A; Nukala PK; Palakurthi SS; Khan W
    Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36769023
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Microfluidic production of mRNA-loaded lipid nanoparticles for vaccine applications.
    Lopes C; Cristóvão J; Silvério V; Lino PR; Fonte P
    Expert Opin Drug Deliv; 2022 Oct; 19(10):1381-1395. PubMed ID: 36223174
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chemistry of Lipid Nanoparticles for RNA Delivery.
    Eygeris Y; Gupta M; Kim J; Sahay G
    Acc Chem Res; 2022 Jan; 55(1):2-12. PubMed ID: 34850635
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Current state of, prospects for, and obstacles to mRNA vaccine development.
    Aljabali AAA; Bashatwah RM; Obeid MA; Mishra V; Mishra Y; Serrano-Aroca Á; Lundstrom K; Tambuwala MM
    Drug Discov Today; 2023 Feb; 28(2):103458. PubMed ID: 36427779
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gastrointestinal Delivery of an mRNA Vaccine Using Immunostimulatory Polymeric Nanoparticles.
    Kim H; Kirtane AR; Kim NY; Rajesh NU; Tang C; Ishida K; Hayward AM; Langer R; Traverso G
    AAPS J; 2023 Aug; 25(5):81. PubMed ID: 37589795
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Developing mRNA for Therapy.
    Karikó K
    Keio J Med; 2022; 71(1):31. PubMed ID: 35342149
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical Development of mRNA Vaccines: Challenges and Opportunities.
    August A; Brito L; Paris R; Zaks T
    Curr Top Microbiol Immunol; 2022; 440():167-186. PubMed ID: 35906319
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Considerations on the Design of Lipid-based mRNA Vaccines Against Cancer.
    Meulewaeter S; Zhang Y; Wadhwa A; Fox K; Lentacker I; Harder KW; Cullis PR; De Smedt SC; Cheng MHY; Verbeke R
    J Mol Biol; 2024 Jan; 436(2):168385. PubMed ID: 38065276
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Perspectives and Prospects on mRNA Vaccine Development for COVID-19.
    Jin L; Han Z; Zhao P; Sun K
    Curr Med Chem; 2022; 29(23):3991-3996. PubMed ID: 35170403
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism.
    Amanpour S
    Arch Razi Inst; 2021 Mar; 76(1):1-6. PubMed ID: 33818952
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lipid Nanoparticles as Promising Carriers for mRNA Vaccines for Viral Lung Infections.
    Hajiaghapour Asr M; Dayani F; Saedi Segherloo F; Kamedi A; Neill AO; MacLoughlin R; Doroudian M
    Pharmaceutics; 2023 Apr; 15(4):. PubMed ID: 37111613
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nucleoside Modified mRNA Vaccines for Infectious Diseases.
    Pardi N; Weissman D
    Methods Mol Biol; 2017; 1499():109-121. PubMed ID: 27987145
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.